Document ID: chunk:federal_register_of_legislation:F2023L00472:reg:8
Version: federal_register_of_legislation:F2023L00472
Segment Type: reg
Provision Reference: reg 8
Character Range: 3149–5525

8               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting plantar fibromatosis or death from plantar fibromatosis with the circumstances of a person's relevant service:
(1)          having alcohol use disorder at the time of the clinical onset of plantar fibromatosis;
(2)          having alcoholic liver cirrhosis at the time of the clinical onset of plantar fibromatosis;
(3)          having diabetes mellitus before the clinical onset of plantar fibromatosis;
(4)          having epilepsy at the time of the clinical onset of plantar fibromatosis;
(5)          taking phenobarbital or primidone regularly for the treatment of epilepsy:
(a)          for a continuous period of at least 2 years before the clinical onset of plantar fibromatosis; and
(b)          where this treatment has ceased, the clinical onset of plantar fibromatosis has occurred within the 1 year of cessation;
(6)          taking vemurafenib within the 2 years before the clinical onset of plantar fibromatosis;
(7)          having trauma to the affected foot within the 1 year before the clinical onset of plantar fibromatosis;
Note: trauma is defined in the Schedule 1 –Dictionary.
(8)          having alcohol use disorder at the time of the clinical worsening of plantar fibromatosis;
(9)          having alcoholic liver cirrhosis at the time of the clinical worsening of plantar fibromatosis;
(10)      having diabetes mellitus before the clinical worsening of plantar fibromatosis;
(11)      having epilepsy at the time of the clinical worsening of plantar fibromatosis;
(12)      taking phenobarbital or primidone regularly for the treatment of epilepsy:
(a)          for a continuous period of at least 2 years before the clinical worsening of plantar fibromatosis; and
(b)          where this treatment has ceased, the clinical worsening of plantar fibromatosis has occurred within the 1 year of cessation;
(13)      taking vemurafenib within the 2 years before the clinical worsening of plantar fibromatosis;
(14)      having trauma to the affected foot within the 1 year before the clinical worsening of plantar fibromatosis;
Note: trauma is defined in the Schedule 1 –Dictionary.
(15)      inability to obtain appropriate clinical management for plantar fibromatosis.